WEBULL
WebtradeDownload

Enliven Therapeutics (ELVN) As ENABLE Data Return Puts Its 4.8x P B In Focus

Simply Wall St · 1d ago

Enliven Therapeutics (ELVN) is back in focus after announcing it will present encore data from its ENABLE Phase 1 trial of ELVN-001 for previously treated chronic myeloid leukemia at the SOHO 2026 meeting.

The encore ENABLE data arrive after a sharp rerating in Enliven Therapeutics, with the share price at US$59.01 and a year to date share price return of 279.73%, plus a 90 day share price return of 66.27% that points to strong recent momentum despite some short term volatility.

Scan other high momentum biotech stocks showing similar trial driven interest through our curated list of 20 high quality undiscovered gems while you assess what Enliven Therapeutics is pricing in.

Bulls see Enliven Therapeutics as a potential best in class CML story that recent data is only starting to reflect. Bears see a Phase 1 asset and a US$4.2b valuation as hard to square. Which case fits the numbers?

Preferred Price-to-Book Ratio of 4.8x: Is It Justified for Enliven Therapeutics?

Valuation for Enliven Therapeutics is currently framed around its price-to-book ratio of 4.8x, which sits between its direct peer group and the broader US Pharmaceuticals sector.

The price-to-book ratio compares a company’s market value to its net assets on the balance sheet. For a clinical stage biopharma company with no meaningful revenue and ongoing losses, investors often lean on this metric to judge how much they are paying for cash, intellectual property and pipeline potential rather than current earnings.

Analysts assessing Enliven Therapeutics highlight that on a preferred multiple basis it is described as good value versus its immediate peers at 9.2x P/B, yet expensive versus the wider US Pharmaceuticals industry at 2.5x P/B. That points to a market that is assigning a premium to ELVN’s pipeline and projected revenue growth, while still pricing it below some of the higher priced comparables in its specialist peer set.

Against that backdrop, the 4.8x P/B level looks high relative to the broader industry but low relative to closer peers, which creates a valuation gap investors will need to judge for themselves.

See what the numbers say about this price — find out in our valuation breakdown.

Result: Price-to-book of 4.8x (ABOUT RIGHT)

However, Enliven Therapeutics still faces early stage clinical risk, and its US$4.2b market cap leaves little room if trial data or funding conditions weaken.

Find out about the key risks to this Enliven Therapeutics narrative.

Next Steps

If the mixed sentiment around Enliven Therapeutics leaves you unsure, act while the data is fresh and review the 2 key rewards and 4 important warning signs in the 2 key rewards and 4 important warning signs.

Looking for more investment ideas beyond Enliven Therapeutics?

Do not stop with Enliven Therapeutics. Use the Simply Wall Street Screener to spot fresh stock ideas that fit your style before others start paying attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.